Abstracts tagged "Patient-reported outcome measures and systemic sclerosis"

Abstract Number: 738 • 2017 ACR/ARHP Annual Meeting
Prospective Validation of the Systemic Sclerosis Skin Symptoms Patient-Reported Outcome (SSPRO) in a Phase 2 Trial of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Ada Man¹, Nancy Dgetluck² and Barbara White³, ¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ²Biostatistics, Corbus Pharmaceuticals, Norwood, MA, ³Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Skin thickening is the defining manifestation of dcSSc. A dcSSc patient’s assessment of their skin involvement can provide information about how that patient feels…
Abstract Number: 837 • 2016 ACR/ARHP Annual Meeting
Development of a Skin-Specific Scleroderma Patient Reported Outcome Instrument
Ada Man¹, Jeannette K. Correa², Jessica Ziemek³, David T. Felson⁴ and Robert Lafyatis⁵, ¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ²Psychology, Boston University, Boston, MA, ³Rheumatology, Boston University, Boston, MA, ⁴Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Skin fibrosis is the hallmark of SSc and may lead to significantly reduced quality of life in ways that may not be directly proportional…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].